AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 26458964 — intervention group
Group type: EXPERIMENTAL
Intervention: Informed shared decision-making program (decision coaching by specialized nurses, evidence-based patient decision aid, training of physicians and nurses)
Number of subjects: 192
Study 26458964 — intervention group
Group type: EXPERIMENTAL
Intervention: Informed shared decision-making program
Number of subjects: 192
Study 26458964 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 192
Study 22933814 — intervention group
Group type: EXPERIMENTAL
Intervention: Levetiracetam (LEV)
Number of subjects: 1688
Study 22933814 — intervention group
Group type: COMPARATOR
Intervention: Standard AEDs (VPA‐ER)
Number of subjects: 1688
Study 21471428 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-management intervention program based on motivational interviewing
Number of subjects: 21
Study 19481792 — intervention group
Group type: EXPERIMENTAL
Intervention: XP Bond (etch-and-rinse adhesive using moist bonding)
Number of subjects: 0
Study 19481792 — intervention group
Group type: EXPERIMENTAL
Intervention: XP Bond (using dry bonding)
Number of subjects: 0
Study 19481792 — intervention group
Group type: EXPERIMENTAL
Intervention: Adper Prompt L-Pop (self-etching adhesive)
Number of subjects: 0
Study 19481792 — intervention group
Group type: EXPERIMENTAL
Intervention: PAA (as the sole biomimetic analog)
Number of subjects: 0
Study 19481792 — intervention group
Group type: EXPERIMENTAL
Intervention: PAA and PVPA (as dual biomimetic analogs)
Number of subjects: 0
Study 19481792 — intervention group
Group type: COMPARATOR
Intervention: Control medium (set Portland cement and simulated body fluid without biomimetic analog)
Number of subjects: 0
Study 17944274 — intervention group
Group type: EXPERIMENTAL
Intervention: Live, attenuated intranasal influenza vaccine
Number of subjects: 0
Study 17944274 — intervention group
Group type: EXPERIMENTAL
Intervention: Monoclonals for respiratory syncytial virus (RSV)
Number of subjects: 0
Study 17944274 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel inhibitors for influenza, RSV, and rhinovirus infections
Number of subjects: 0
Study 17944274 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiviral therapies and vaccine strategies
Number of subjects: 0
Study 15081561 — intervention group
Group type: EXPERIMENTAL
Intervention: Red palm olein (RPO)
Number of subjects: 59
Study 15081561 — intervention group
Group type: EXPERIMENTAL
Intervention: Palm olein (POL)
Number of subjects: 59
Study 15081561 — intervention group
Group type: COMPARATOR
Intervention: Sunflower oil (SFO)
Number of subjects: 59
Study 11268947 — intervention group
Group type: EXPERIMENTAL
Intervention: MFL (Methotrexate 100 mg/m2 and 5-FU 600 mg/m2 followed by leucovorin rescue)
Number of subjects: 55
Study 11268947 — intervention group
Group type: COMPARATOR
Intervention: UFT-MMC (Mitomycin C 12 mg/m2 intraoperatively and 6 mg/m2 every other week for 2 months, oral UFT 375 mg/m2/day for 3 years or longer)
Number of subjects: 55
Study 11268947 — intervention group
Group type: EXPERIMENTAL
Intervention: MFL (Methotrexate and 5-FU followed by leucovorin rescue)
Number of subjects: 55
Study 11268947 — intervention group
Group type: COMPARATOR
Intervention: UFT-MMC (Mitomycin C and UFT)
Number of subjects: 55
Study 9917606 — intervention group
Group type: EXPERIMENTAL
Intervention: Cementless taper design femoral components
Number of subjects: 1000
Study 9917606 — intervention group
Group type: COMPARATOR
Intervention: Cemented femoral implants
Number of subjects: 1000
Study 7819596 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulins (100 mg/kg)
Number of subjects: 61
Study 7819596 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulins (250 mg/kg)
Number of subjects: 61
Study 7819596 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulins (400 mg/kg)
Number of subjects: 61
Study 7819596 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 61
Study 3278367 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 g apple pectin USP powder twice daily
Number of subjects: 83
Study 3278367 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 mg ranitidine at night
Number of subjects: 83
Study 3278367 — intervention group
Group type: COMPARATOR
Intervention: One tablet matching ranitidine placebo at night
Number of subjects: 83
Study 31801404 — intervention group
Group type: EXPERIMENTAL
Intervention: Broadband light (BBL) treatment
Number of subjects: 25
Study 31801404 — intervention group
Group type: COMPARATOR
Intervention: Control (untreated side)
Number of subjects: 25
Study 31359829 — intervention group
Group type: EXPERIMENTAL
Intervention: Romiplostim administration after transplantation
Number of subjects: 93
Study 29361348 — intervention group
Group type: EXPERIMENTAL
Intervention: Plinth-based trunk exercise regime
Number of subjects: 108
Study 29361348 — intervention group
Group type: EXPERIMENTAL
Intervention: Swiss ball-based trunk exercise regime
Number of subjects: 108
Study 29361348 — intervention group
Group type: COMPARATOR
Intervention: Standard physiotherapy (Control)
Number of subjects: 108
Study 27002107 — intervention group
Group type: EXPERIMENTAL
Intervention: FOLFOX plus cetuximab (arm A)
Number of subjects: 153
Study 27002107 — intervention group
Group type: COMPARATOR
Intervention: FOLFOX (arm B)
Number of subjects: 153
Study 25394434 — intervention group
Group type: EXPERIMENTAL
Intervention: Cellulose dialyzer
Number of subjects: 73
Study 25394434 — intervention group
Group type: EXPERIMENTAL
Intervention: Polysulfone dialyzer
Number of subjects: 73
Study 23778995 — intervention group
Group type: EXPERIMENTAL
Intervention: rhTPO (300 IU/kg Qd)
Number of subjects: 40
Study 23778995 — intervention group
Group type: COMPARATOR
Intervention: Control (conventional systemic therapy)
Number of subjects: 40
Study 23778995 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 40
Study 20412149 — intervention group
Group type: EXPERIMENTAL
Intervention: Xenon anaesthesia
Number of subjects: 114
Study 20412149 — intervention group
Group type: COMPARATOR
Intervention: Propofol anaesthesia
Number of subjects: 114
Study 20412149 — intervention group
Group type: EXPERIMENTAL
Intervention: Bispectral index
Number of subjects: 114
Study 18258383 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensity-modulated radiotherapy (IMRT)
Number of subjects: 23
Study 18258383 — intervention group
Group type: COMPARATOR
Intervention: Conventional radiotherapy (historical control)
Number of subjects: 23
Study 17058828 — intervention group
Group type: EXPERIMENTAL
Intervention: Ginaton 1 mg/kg by intravenous dripping before open heart for CPB
Number of subjects: 60
Study 17058828 — intervention group
Group type: COMPARATOR
Intervention: Normal saline
Number of subjects: 60
Study 12954825 — intervention group
Group type: EXPERIMENTAL
Intervention: Proximally porous‐coated titanium stem with hydroxyapatite coating
Number of subjects: 50
Study 12954825 — intervention group
Group type: COMPARATOR
Intervention: Proximally porous‐coated titanium stem without hydroxyapatite coating
Number of subjects: 50
Study 12954825 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 50
Study 10720289 — intervention group
Group type: EXPERIMENTAL
Intervention: Cladribine 0.07 mg/kg/day for 5 consecutive days every 4 weeks for two cycles (total dose 0.7 mg/kg)
Number of subjects: 159
Study 10720289 — intervention group
Group type: EXPERIMENTAL
Intervention: Cladribine 0.07 mg/kg/day for 5 consecutive days every 4 weeks for six cycles (total dose 2.1 mg/kg)
Number of subjects: 159
Study 10720289 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 159
Study 8645512 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole: an initial bolus of 80 mg + perfusion of 3.3 mg/h
Number of subjects: 47
Study 8645512 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole: an initial bolus of 80 mg + 40 mg/12 h
Number of subjects: 47
Study 8645512 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole: 40 mg/8 h
Number of subjects: 47
Study 8645512 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine: perfusion of 12.5 mg/h
Number of subjects: 47
Study 8645512 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine: 50 mg/4 h
Number of subjects: 47
Study 1511370 — intervention group
Group type: EXPERIMENTAL
Intervention: Frequent follow-up (1 and 3 years after initial polypectomy)
Number of subjects: 9112
Study 1511370 — intervention group
Group type: COMPARATOR
Intervention: Less frequent follow-up (3 years)
Number of subjects: 9112
Study 6744886 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 29719093 — intervention group
Group type: EXPERIMENTAL
Intervention: Interpersonal psychotherapy for mood and behavior dysregulation (IPT‐MBD)
Number of subjects: 19
Study 29719093 — intervention group
Group type: COMPARATOR
Intervention: Treatment-as-usual (TAU)
Number of subjects: 19
Study 26621326 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine fasting
Number of subjects: 60
Study 26621326 — intervention group
Group type: COMPARATOR
Intervention: Placebo fasting
Number of subjects: 60
Study 26621326 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine meal
Number of subjects: 60
Study 26621326 — intervention group
Group type: COMPARATOR
Intervention: Placebo meal
Number of subjects: 60
Study 24873996 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregnant women with PCOS
Number of subjects: 150
Study 21984039 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal hysterectomy with BiClamp(®) and multimodal anaesthesia (group A)
Number of subjects: 60
Study 21984039 — intervention group
Group type: COMPARATOR
Intervention: Vaginal hysterectomy with spinal anaesthesia (group B)
Number of subjects: 60
Study 19684633 — intervention group
Group type: EXPERIMENTAL
Intervention: Total body MRI-governed involved compartment irradiation (ICI) followed by high-dose chemotherapy (HDC) and stem cell rescue (SCR)
Number of subjects: 37
Study 19684633 — intervention group
Group type: COMPARATOR
Intervention: European Intergroup Cooperative Ewing Sarcoma Study-92 (EICESS-92) protocol
Number of subjects: 37
Study 18929202 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-arm cast extended to the proximal interphalangeal joint with a 3-point mold (MCP-ext)
Number of subjects: 81
Study 18929202 — intervention group
Group type: COMPARATOR
Intervention: Short-arm cast with volar outriggers (SAC-VOR)
Number of subjects: 81
Study 18929202 — intervention group
Group type: EXPERIMENTAL
Intervention: MCP-ext
Number of subjects: 81
Study 18929202 — intervention group
Group type: COMPARATOR
Intervention: SAC-VOR
Number of subjects: 81
Study 15925814 — intervention group
Group type: EXPERIMENTAL
Intervention: PEFG regimen (40 mg/m2 cisplatin, 40 mg/m2 epirubicin, 600 mg/m2 gemcitabine, 200 mg/m2 fluorouracil)
Number of subjects: 99
Study 15925814 — intervention group
Group type: COMPARATOR
Intervention: Gemcitabine alone (1000 mg/m2)
Number of subjects: 99
Study 15925814 — intervention group
Group type: EXPERIMENTAL
Intervention: PEFG regimen
Number of subjects: 99
Study 15925814 — intervention group
Group type: COMPARATOR
Intervention: Gemcitabine alone
Number of subjects: 99
Study 12689974 — intervention group
Group type: EXPERIMENTAL
Intervention: Interleukin-2 receptor antibodies
Number of subjects: 1858
Study 10646048 — intervention group
Group type: EXPERIMENTAL
Intervention: Racecadotril (100 mg three times daily)
Number of subjects: 157
Study 10646048 — intervention group
Group type: COMPARATOR
Intervention: Loperamide (2 mg after each diarrhoeic stool)
Number of subjects: 157
Study 8906513 — intervention group
Group type: EXPERIMENTAL
Intervention: Isolated systolic hypertension
Number of subjects: 885
Study 8906513 — intervention group
Group type: EXPERIMENTAL
Intervention: Antihypertensive medication
Number of subjects: 885
Study 8906513 — intervention group
Group type: EXPERIMENTAL
Intervention: DBP and SBP levels
Number of subjects: 885
Study 1905051 — intervention group
Group type: EXPERIMENTAL
Intervention: Skills-building intervention (five sessions of small groups)
Number of subjects: 91
Study 1905051 — intervention group
Group type: COMPARATOR
Intervention: Information-only control group
Number of subjects: 91
Study 7201837 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg/kg antipyrine (phenazone) administered intravenously (i.v.)
Number of subjects: 12
Study 7201837 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg/kg antipyrine (phenazone) administered orally (p.o.)
Number of subjects: 12
Study 7201837 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg/kg antipyrine (phenazone) administered i.v. in smokers
Number of subjects: 12
Study 7201837 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg/kg antipyrine (phenazone) administered i.v. in non-smokers
Number of subjects: 12
Study 7201837 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg/kg antipyrine (phenazone) in smokers
Number of subjects: 12
Study 31909448 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerebrolysin
Number of subjects: 0
Study 31909448 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 30665829 — intervention group
Group type: EXPERIMENTAL
Intervention: telmisartan/amlodipine/rosuvastatin (80 mg/10 mg plus 20 mg)
Number of subjects: 148
Study 30665829 — intervention group
Group type: COMPARATOR
Intervention: telmisartan/rosuvastatin (80 mg plus 20 mg)
Number of subjects: 148
Study 30665829 — intervention group
Group type: COMPARATOR
Intervention: telmisartan/amlodipine (80 mg/10 mg)
Number of subjects: 148
Study 30544421 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep neuromuscular block (NMB)
Number of subjects: 196
Study 30544421 — intervention group
Group type: COMPARATOR
Intervention: Moderate neuromuscular block (NMB)
Number of subjects: 196
Study 27502582 — intervention group
Group type: EXPERIMENTAL
Intervention: Etoricoxib 60 mg
Number of subjects: 1404
Study 27502582 — intervention group
Group type: EXPERIMENTAL
Intervention: Etoricoxib 90 mg
Number of subjects: 1404
Study 27502582 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1404
Study 27502582 — intervention group
Group type: EXPERIMENTAL
Intervention: Etoricoxib 60 mg to 90 mg escalation
Number of subjects: 1404
Study 27502582 — intervention group
Group type: EXPERIMENTAL
Intervention: Etoricoxib 60 mg steady dose
Number of subjects: 1404
Study 24149215 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer-led HIV intervention
Number of subjects: 0
Study 22238577 — intervention group
Group type: EXPERIMENTAL
Intervention: L-DOPA (0, 100/25, 200/50 mg, Sinemet)
Number of subjects: 0
Study 18199500 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine (10 mg daily for 8 weeks)
Number of subjects: 45
Study 18199500 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study 17187585 — intervention group
Group type: EXPERIMENTAL
Intervention: Fatty meal (800 kcal, 60% calories from fat)
Number of subjects: 21
Study 17187585 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbohydrate meal (800 kcal)
Number of subjects: 21
Study 17187585 — intervention group
Group type: COMPARATOR
Intervention: Control group (11 participants)
Number of subjects: 21
Study 15121931 — intervention group
Group type: EXPERIMENTAL
Intervention: Parenteral glutamine supplementation
Number of subjects: 1433
Study 15121931 — intervention group
Group type: COMPARATOR
Intervention: Control (TrophAmine)
Number of subjects: 1433
Study 28692301 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3 (3.5 mg or 140,000 IU biweekly for 8 weeks)
Number of subjects: 390
Study 28692301 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 390
Study 10626290 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximal androgen blockade (LHRH agonists combined with antiandrogens)
Number of subjects: 0
Study 10626290 — intervention group
Group type: EXPERIMENTAL
Intervention: LH-RH analogues alone or in combination with antiandrogens
Number of subjects: 0
Study 10626290 — intervention group
Group type: EXPERIMENTAL
Intervention: Early androgen deprivation
Number of subjects: 0
Study 10626290 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant or adjuvant use of LH-RH analogues
Number of subjects: 0
Study 8791042 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitomycin C
Number of subjects: 132
Study 8791042 — intervention group
Group type: EXPERIMENTAL
Intervention: Epirubicin
Number of subjects: 132
Study 1560168 — intervention group
Group type: EXPERIMENTAL
Intervention: Antigen challenge (0.004 to 100 PNU/ml)
Number of subjects: 44
Study 1560168 — intervention group
Group type: COMPARATOR
Intervention: Antigen challenge in nonatopic control subjects
Number of subjects: 44
Study 1560168 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose antigen challenge (>= 1 PNU/ml) in atopic subjects
Number of subjects: 44
Study 6585529 — intervention group
Group type: EXPERIMENTAL
Intervention: Amalgam restorations made of five conventional composition alloys and one high copper alloy.
Number of subjects: 57
Study 6585529 — intervention group
Group type: EXPERIMENTAL
Intervention: Amalgam restorations made by two operators.
Number of subjects: 57
Study 6585529 — intervention group
Group type: EXPERIMENTAL
Intervention: Amalgam restorations after 1 year.
Number of subjects: 57
Study 6585529 — intervention group
Group type: EXPERIMENTAL
Intervention: Amalgam restorations over 5 years.
Number of subjects: 57
Study 31320490 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple tracer (blue dye, indocyanine green, and Tc99)
Number of subjects: 157
Study 31320490 — intervention group
Group type: COMPARATOR
Intervention: Double tracer (indocyanine green and Tc99)
Number of subjects: 157
Study 29903674 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvanted recombinant zoster vaccine (RZV) co-administered with 23-valent pneumococcal polysaccharide vaccine (PPSV23)
Number of subjects: 865
Study 29903674 — intervention group
Group type: COMPARATOR
Intervention: Sequential administration of PPSV23 followed by RZV
Number of subjects: 865
Study 26818636 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-invasive programmed stimulation (NIPS)
Number of subjects: 150
Study 26818636 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 150
Study 24500537 — intervention group
Group type: EXPERIMENTAL
Intervention: Gait retraining (supervised exercises for neuromuscular control and flexibility, three sessions per week; biofeedback, one session per week)
Number of subjects: 166
Study 24500537 — intervention group
Group type: COMPARATOR
Intervention: Control group (usual military training regimen without gait retraining)
Number of subjects: 166
Study 22948452 — intervention group
Group type: EXPERIMENTAL
Intervention: Small intestine submucosa graft
Number of subjects: 56
Study 22948452 — intervention group
Group type: COMPARATOR
Intervention: Traditional colporrhaphy
Number of subjects: 56
Study 21056804 — intervention group
Group type: EXPERIMENTAL
Intervention: FIO(2) = 0.8 (Group G80)
Number of subjects: 120
Study 21056804 — intervention group
Group type: EXPERIMENTAL
Intervention: FIO(2) = 0.5 (Group G50)
Number of subjects: 120
Study 21056804 — intervention group
Group type: COMPARATOR
Intervention: FIO(2) = 0.3 (Group G30)
Number of subjects: 120
Study 17693652 — intervention group
Group type: EXPERIMENTAL
Intervention: Pegylated interferon-alpha2b (P-IFN)
Number of subjects: 60
Study 17693652 — intervention group
Group type: COMPARATOR
Intervention: Interferon-alpha2b (IFN)
Number of subjects: 60
Study 15767215 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term stavudine therapy (40 mg single dose)
Number of subjects: 36
Study 15767215 — intervention group
Group type: COMPARATOR
Intervention: Single-dose stavudine treatment (40 mg)
Number of subjects: 36
Study 12224599 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily combination of 60 mg soy isoflavones, 100 mg dong quai, and 50 mg black cohosh for 24 weeks
Number of subjects: 49
Study 12224599 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment for 24 weeks
Number of subjects: 49
Study 10223772 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine
Number of subjects: 8
Study 10223772 — intervention group
Group type: COMPARATOR
Intervention: Ranitidine
Number of subjects: 8
Study 10223772 — intervention group
Group type: COMPARATOR
Intervention: Ebrotidine
Number of subjects: 8
Study 8714852 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium channel antagonists (Nicardipine, Verapamil, Diltiazem) administered by iontophoresis
Number of subjects: 3
Study 8714852 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium channel antagonists (Nicardipine, Verapamil, Diltiazem) administered by iontophoresis in combination with lidocaine
Number of subjects: 3
Study 8714852 — intervention group
Group type: COMPARATOR
Intervention: Lidocaine administered alone
Number of subjects: 3
Study 31079232 — intervention group
Group type: EXPERIMENTAL
Intervention: Active low-level laser therapy (LLLT)
Number of subjects: 22
Study 31079232 — intervention group
Group type: COMPARATOR
Intervention: Placebo laser therapy
Number of subjects: 22
Study 30665306 — intervention group
Group type: EXPERIMENTAL
Intervention: Constant force-induced unfolding of ubiquitin protein at about 400 pN
Number of subjects: 0
Study 30665306 — intervention group
Group type: EXPERIMENTAL
Intervention: Pearson correlation coefficient analysis
Number of subjects: 0
Study 30665306 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidimensional transition-state theory
Number of subjects: 0
Study 27829181 — intervention group
Group type: EXPERIMENTAL
Intervention: Thoracic epidural block (TEB)
Number of subjects: 60
Study 27829181 — intervention group
Group type: COMPARATOR
Intervention: General anesthesia alone
Number of subjects: 60
Study 25293650 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychotherapy and pharmacotherapy sessions
Number of subjects: 403
Study 25293650 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 403
Study 25293650 — intervention group
Group type: EXPERIMENTAL
Intervention: Race as a predictor of response, remission, or relapse
Number of subjects: 403
Study 23441100 — intervention group
Group type: EXPERIMENTAL
Intervention: Freckling score
Number of subjects: 3123
Study 23441100 — intervention group
Group type: EXPERIMENTAL
Intervention: Tanning score
Number of subjects: 3123
Study 21442803 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical nerve stimulation (TENS) at Dingchuan (EX-B 1) with frequency of 4 Hz and wave width of 200 ms
Number of subjects: 40
Study 21442803 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation without current output at Dingchuan (EX-B 1)
Number of subjects: 40
Study 19047293 — intervention group
Group type: EXPERIMENTAL
Intervention: Sorafenib 400 mg twice daily for 28 days in each 4-week cycle
Number of subjects: 23
Study 16944408 — intervention group
Group type: EXPERIMENTAL
Intervention: Reboxetine (4 mg/bd)
Number of subjects: 20